Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cortexyme, Inc. - Common Stock (NQ:CRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 29, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cortexyme, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
The 10 Most Shorted Stocks Right Now for Friday, Dec. 17
Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! 
Via InvestorPlace
5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYS... 
Via Benzinga
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
From Cortexyme, Inc.
Via Business Wire
Could It Finally Be Time To Step Up to The Plate With GME Stock?
There's mixed messages being sent to bullish investors other than apes, but the next inning or two of play look promising for GME stock. 
Via InvestorPlace
Cassava Pops As Cortexyme Dives — Why One Alzheimer's Stock Is 'Back On Track'
An analyst says Cassava is on track, but Cortexyme took another beating Thursday. 
Via Investor's Business Daily
Why Are Cortexyme Shares Falling Today?
Cortexyme Inc (NASDAQ: CRTX) has presented additional data from its Phase 2/3 GAIN Trial at the Clinical Trials on Alzheimer's Disease Conference. The... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liquidia (NASDAQ:LQDA) stock inc... 
Via Benzinga
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
From Cortexyme, Inc.
Via Business Wire
The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Commences Late-Stage Study Of Heart Failure Treatment Merck &... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
From Cortexyme, Inc.
Via Business Wire
This Is What Whales Are Betting On Cortexyme
Someone with a lot of money to spend (and possibly insider knowledge) has taken a bullish stance on Cortexyme (NASDAQ:CRTX). And retail traders should know. We noticed this today... 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers Avis Budget Group, Inc. (NASDAQ: CAR) shares climbed 108.3% to close at $357.17 on Tuesday after the company reported better-than-expected Q3 adjusted EPS and sales... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Down 76%: Is Cortexyme Stock a Bargain?
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial. 
Via The Motley Fool
Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors
Another new drug candidate for the treatment of Alzheimer's disease failed miserably in a clinical trial. 
Via The Motley Fool
64 Biggest Movers From Yesterday
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 83.4% to close at $5.30. Siyata Mobile released their Q2 earnings on an October 15th call that included CEO Marc... 
Via Benzinga
CRTX Stock: What to Know as Cortexyme Plummets 75%
Today, investors in CRTX stock lament a rather poor announcement from the company that a key clinical trial missed its primary endpoint. 
Via InvestorPlace
Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge
Toward the end of trading Wednesday, the Dow traded down 0.23% to 35,674.01 while the NASDAQ rose 0.81% to 15,358.79. The S&P also rose, gaining 0.14% to 4,581.2. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Cortexyme Shares Are Falling
Cortexyme Inc (NASDAQ: CRTX) shares are trading lower after the company's Phase 2/3 GAIN trial did not meet its co-primary endpoints. Cortexyme says they will present the... 
Via Benzinga
Here's Why Cortexyme Is Imploding on Wednesday
An Alzheimer's disease trial failure was much worse than the company's relatively upbeat look forward suggests. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Nurix Therapeutics (NASDAQ:NRIX) stock moved upwards by 15.4% to $33.42 during Wednesday's regular session. Trading volume for Nurix Therapeutics's stock... 
Via Benzinga
Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher
Midway through trading Wednesday, the Dow traded down 0.30% to 35,648.39 while the NASDAQ rose 0.32% to 15,283.97. The S&P also fell, dropping 0.03% to 4,573.51. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mid-Morning Market Update: Markets Rise; Coca-Cola Tops Q3 Views
Following the market opening Wednesday, the Dow traded up 0.16% to 35,814.95 while the NASDAQ rose 0.24% to 15,271.98. The S&P also rose, gaining 0.12% to 4,580.19. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2021
Upgrades According to Credit Suisse, the prior rating for Mercer International Inc (NASDAQ: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Bio-Path Holdings (NASDAQ:BPTH) shares moved upwards by 9.69% to $5.43 during Wednesday's pre-market session. The company's market cap stands at $37.7... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James raised Alphabet Inc. (NASDAQ:GOOGL 
Via Benzinga
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers China XD Plastics Company Limited (NASDAQ: CXDC) rose 139% to $1.40 in pre-market trading after jumping around 30% on Tuesday. Guardion Health Sciences, Inc. (NASDAQ:... 
Via Benzinga
Why Cortexyme Shares Are Plunging 70% After Hours
Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc (NASDAQ: CRTX)... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback